{"id":"W3207994228","doi":"10.1182/blood-2021-148813","title":"Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; CD38; Pomalidomide; Refractory (planetary science); Multiple myeloma; Oncology; Tumor lysis syndrome; Immunology; Gastroenterology; Lenalidomide; Chemotherapy; Stem cell; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002540394,0.001323438,0.002114405,0.0004910743,0.0006351038,0.001143724,0.000855879,0.001859464,0.008893364],"category_scores_gemma":[0.001249728,0.0005537352,0.001733313,0.0005545219,0.0005766068,0.0007746336,0.0005075862,0.002836276,0.002226026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001534703,"about_ca_system_score_gemma":0.001837934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001129784,"about_ca_topic_score_gemma":0.003548495,"domain_scores_codex":[0.9992689,0.0003501037,0.00006147657,0.0001084098,0.00009969567,0.0001113498],"domain_scores_gemma":[0.9990724,0.0001365037,0.000183889,0.00007087112,0.00008861459,0.0004476395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.675475,0.0498277,0.01037598,0.002889931,0.003351814,0.0006131154,0.0003113394,0.00186152,0.05887874,0.0003624612,0.02265934,0.1733931],"study_design_scores_gemma":[0.7227407,0.2351578,0.02328543,0.0001893135,0.0009952692,0.0006012517,0.00006664639,0.0006153015,0.003833679,0.000278128,0.01220188,0.00003464388],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9344778,0.01150441,0.001904113,0.003556313,0.0004558162,0.02077061,0.01824756,0.0005863492,0.008497083],"genre_scores_gemma":[0.9376767,0.004723316,0.006376876,0.007104688,0.0004058409,0.01577438,0.01965625,0.0001558996,0.008125911],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008893364,"threshold_uncertainty_score":0.0297513,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0182572283124126,"score_gpt":0.2827512217054763,"score_spread":0.2644939933930637,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}